Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-03-15

AUTHORS

Khurram J Khan, Thomas A Ullman, Alexander C Ford, Maria T Abreu, A Abadir, John K Marshall, Nicholas J Talley, Paul Moayyedi

ABSTRACT

The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD. More... »

PAGES

661

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/ajg.2011.72

DOI

http://dx.doi.org/10.1038/ajg.2011.72

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023776266

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21407187


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colitis, Ulcerative", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Crohn Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rifamycins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Secondary Prevention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Khurram J", 
        "id": "sg:person.0722775106.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722775106.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Mount Sinai School of Medicine, New York, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.59734.3c", 
          "name": [
            "The Mount Sinai School of Medicine, New York, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ullman", 
        "givenName": "Thomas A", 
        "id": "sg:person.01031655740.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031655740.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK", 
          "id": "http://www.grid.ac/institutes/grid.418161.b", 
          "name": [
            "Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ford", 
        "givenName": "Alexander C", 
        "id": "sg:person.01251421433.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251421433.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Miller School of Medicine, University of Miami, Miami, Florida, USA", 
          "id": "http://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "Miller School of Medicine, University of Miami, Miami, Florida, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abreu", 
        "givenName": "Maria T", 
        "id": "sg:person.0606477677.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606477677.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abadir", 
        "givenName": "A", 
        "id": "sg:person.01150145573.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150145573.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marshall", 
        "givenName": "John K", 
        "id": "sg:person.01267435505.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267435505.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia", 
          "id": "http://www.grid.ac/institutes/grid.266842.c", 
          "name": [
            "Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Talley", 
        "givenName": "Nicholas J", 
        "id": "sg:person.0604330074.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604330074.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University Medical Centre, Hamilton, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.411657.0", 
          "name": [
            "McMaster University Medical Centre, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moayyedi", 
        "givenName": "Paul", 
        "id": "sg:person.01336200702.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336200702.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1111/j.1572-0241.2007.01592.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053234582", 
          "https://doi.org/10.1111/j.1572-0241.2007.01592.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2009.29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027606985", 
          "https://doi.org/10.1038/ajg.2009.29"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050498034", 
          "https://doi.org/10.1038/nature08821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01298873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027500057", 
          "https://doi.org/10.1007/bf01298873"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2011.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012980082", 
          "https://doi.org/10.1038/ajg.2011.58"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2010.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002619249", 
          "https://doi.org/10.1038/ajg.2010.84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2000.01842.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047651520", 
          "https://doi.org/10.1111/j.1572-0241.2000.01842.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2009.315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002445970", 
          "https://doi.org/10.1038/ajg.2009.315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10620-007-9760-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018618582", 
          "https://doi.org/10.1007/s10620-007-9760-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1026648812439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038664726", 
          "https://doi.org/10.1023/a:1026648812439"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-03-15", 
    "datePublishedReg": "2011-03-15", 
    "description": "The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/ajg.2011.72", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1412991", 
        "issn": [
          "0002-9270", 
          "1572-0241"
        ], 
        "name": "The American Journal of Gastroenterology", 
        "publisher": "Wolters Kluwer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "106"
      }
    ], 
    "keywords": [
      "inflammatory bowel disease", 
      "active Crohn's disease", 
      "Crohn's disease", 
      "ulcerative colitis", 
      "antibiotic therapy", 
      "systematic review", 
      "active disease", 
      "bowel disease", 
      "relative risk", 
      "moderate heterogeneity", 
      "perianal CD fistulae", 
      "quiescent Crohn's disease", 
      "active ulcerative colitis", 
      "parallel-group RCT", 
      "definition of remission", 
      "dose of therapy", 
      "different antibiotic combinations", 
      "favor of antibiotics", 
      "random-effects model", 
      "CD fistulae", 
      "quiescent disease", 
      "adult patients", 
      "primary outcome", 
      "treat methodology", 
      "group RCT", 
      "fistula drainage", 
      "antibiotic combinations", 
      "remission", 
      "further trials", 
      "combination drugs", 
      "gut microbiota", 
      "patients", 
      "relapse", 
      "RCTs", 
      "Meta-Analysis", 
      "therapy", 
      "immunological reactions", 
      "disease", 
      "rifamycin derivatives", 
      "antibiotics", 
      "significant effect", 
      "trials", 
      "placebo", 
      "bacterial pathogens", 
      "effects model", 
      "current data", 
      "significant benefits", 
      "review", 
      "colitis", 
      "fistula", 
      "etiology", 
      "metronidazole", 
      "dose", 
      "weeks", 
      "months", 
      "drugs", 
      "eligibility", 
      "ciprofloxacin", 
      "outcomes", 
      "microbiota", 
      "effect", 
      "reviewers", 
      "risk", 
      "heterogeneity", 
      "diverse number", 
      "days", 
      "combination", 
      "drainage", 
      "pathogens", 
      "data", 
      "number", 
      "study", 
      "benefits", 
      "favor", 
      "intention", 
      "results", 
      "definition", 
      "reaction", 
      "derivatives", 
      "model", 
      "mandate", 
      "methodology"
    ], 
    "name": "Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis", 
    "pagination": "661", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023776266"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/ajg.2011.72"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21407187"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/ajg.2011.72", 
      "https://app.dimensions.ai/details/publication/pub.1023776266"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_533.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/ajg.2011.72"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/ajg.2011.72'


 

This table displays all metadata directly associated to this object as RDF triples.

292 TRIPLES      21 PREDICATES      129 URIs      111 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/ajg.2011.72 schema:about N06000ea5f6d543939c38b04887117fc6
2 N088d3f3317234b2793ce640ef508da8c
3 N16164dd18eea4df2b88e5163ee1ae728
4 N215ac401ea9447a989ea11bb1630cd51
5 N2b0f1b608ac64db8aab10a9c969f45d3
6 N342208bfdbd54923958081997aa50659
7 N467a7fdd822442fa97b2a655e94d4c67
8 N47ddfe059cd0458b923fd610ed0df93a
9 N6c54b0f4d0114cfd89cf546b4c50c75e
10 N8532ca4e234b4c24bd00c09844625ac9
11 Na5125856b5a3448abefad35e93f2f99c
12 Nb7e919dbb4be4cd7be07b13329ba23cc
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N8d1701ccce9440c78cbf4ac17f17276a
16 schema:citation sg:pub.10.1007/bf01298873
17 sg:pub.10.1007/s10620-007-9760-1
18 sg:pub.10.1023/a:1026648812439
19 sg:pub.10.1038/ajg.2009.29
20 sg:pub.10.1038/ajg.2009.315
21 sg:pub.10.1038/ajg.2010.84
22 sg:pub.10.1038/ajg.2011.58
23 sg:pub.10.1038/nature08821
24 sg:pub.10.1111/j.1572-0241.2000.01842.x
25 sg:pub.10.1111/j.1572-0241.2007.01592.x
26 schema:datePublished 2011-03-15
27 schema:datePublishedReg 2011-03-15
28 schema:description The etiology of inflammatory bowel disease (IBD) is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn's disease (CD) and ulcerative colitis (UC) to induce remission in active disease to prevent relapse. Current data are conflicting and we therefore conducted a systematic review of randomized controlled trials (RCTs) evaluating antibiotics in IBD. Only parallel group RCTs were considered eligible. Studies with adult patients receiving any dose of therapy for at least 7 days and up to 16 weeks for active disease, or at least 6 months of follow-up for preventing relapse in quiescent disease were analyzed. We included any antibiotics alone or in combination using predefined definitions of remission and relapse. Two reviewers independently assessed eligibility and extracted data. The primary outcome was remission or relapse using an intention-to-treat methodology. The data were summarized using relative risk (RR) and pooled using a random effects model. For active CD, there were 10 RCTs involving 1,160 patients. There was a statistically significant effect of antibiotics being superior to placebo (RR of active CD not in remission=0.85; 95% confidence interval (CI)=0.73-0.99, P=0.03). There was moderate heterogeneity between results (I(2)=48%) and a diverse number of antibiotics were tested (anti-tuberculosis therapy, macrolides, fluroquinolones, 5-nitroimidazoles, and rifaximin) either alone or in combination. Rifamycin derivatives either alone or in combination with other antibiotics appeared to have a significant effect at inducing remission in active CD. In perianal CD fistula there were three trials evaluating 123 patients using either ciprofloxacin or metronidazole. There was a statistically significant effect in reducing fistula drainage (RR=0.8; 95% CI=0.66-0.98) with no heterogeneity (I(2)=0%) and an number needed to treat 5 (95% CI=3-20). For quiescent CD, there were 3 RCTs involving 186 patients treated with different antibiotics combinations (all including antimycobacterials) vs. placebo. There was a statistically significant effect in favor of antibiotics vs. placebo (RR of relapse=0.62; 95% CI=0.46-0.84), with no heterogeneity (I(2)=0%). In active UC, there were 9 RCTs with 662 patients and there was a statistically significant benefit for antibiotics inducing remission (RR of UC not in remission=0.64; 95% CI=0.43-0.96). There was moderate heterogeneity (I(2)=69%) and antibiotics used were all different single or combination drugs. Antibiotic therapy may induce remission in active CD and UC, although the diverse number of antibiotics tested means the data are difficult to interpret. This systematic review is a mandate for further trials of antibiotic therapy in IBD.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf N593e64aedc264b5c9eaaee34bfd88564
32 N8d50da71932344d7a188a7764a0a3e23
33 sg:journal.1412991
34 schema:keywords CD fistulae
35 Crohn's disease
36 Meta-Analysis
37 RCTs
38 active Crohn's disease
39 active disease
40 active ulcerative colitis
41 adult patients
42 antibiotic combinations
43 antibiotic therapy
44 antibiotics
45 bacterial pathogens
46 benefits
47 bowel disease
48 ciprofloxacin
49 colitis
50 combination
51 combination drugs
52 current data
53 data
54 days
55 definition
56 definition of remission
57 derivatives
58 different antibiotic combinations
59 disease
60 diverse number
61 dose
62 dose of therapy
63 drainage
64 drugs
65 effect
66 effects model
67 eligibility
68 etiology
69 favor
70 favor of antibiotics
71 fistula
72 fistula drainage
73 further trials
74 group RCT
75 gut microbiota
76 heterogeneity
77 immunological reactions
78 inflammatory bowel disease
79 intention
80 mandate
81 methodology
82 metronidazole
83 microbiota
84 model
85 moderate heterogeneity
86 months
87 number
88 outcomes
89 parallel-group RCT
90 pathogens
91 patients
92 perianal CD fistulae
93 placebo
94 primary outcome
95 quiescent Crohn's disease
96 quiescent disease
97 random-effects model
98 reaction
99 relapse
100 relative risk
101 remission
102 results
103 review
104 reviewers
105 rifamycin derivatives
106 risk
107 significant benefits
108 significant effect
109 study
110 systematic review
111 therapy
112 treat methodology
113 trials
114 ulcerative colitis
115 weeks
116 schema:name Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
117 schema:pagination 661
118 schema:productId N660022fc619141119b274f6b420ef24c
119 N805590fd3e8f4f9baee9c5ddba0570a6
120 N8dd4598184854c1e86463cf548b7f294
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023776266
122 https://doi.org/10.1038/ajg.2011.72
123 schema:sdDatePublished 2022-09-02T15:54
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher N3494222cc8c7443bb6ae6d48f86d1dec
126 schema:url https://doi.org/10.1038/ajg.2011.72
127 sgo:license sg:explorer/license/
128 sgo:sdDataset articles
129 rdf:type schema:ScholarlyArticle
130 N06000ea5f6d543939c38b04887117fc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Randomized Controlled Trials as Topic
132 rdf:type schema:DefinedTerm
133 N088d3f3317234b2793ce640ef508da8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Treatment Outcome
135 rdf:type schema:DefinedTerm
136 N16164dd18eea4df2b88e5163ee1ae728 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Drug Combinations
138 rdf:type schema:DefinedTerm
139 N18605a0ed18144cc8df71b563e29fa60 rdf:first sg:person.01251421433.66
140 rdf:rest N553675eb66804d648ae6cd119c1f5d2d
141 N1f2d6d8c0c884a1dbf923d17c305155f rdf:first sg:person.01150145573.40
142 rdf:rest N8bb4ce37169c43b1ac69eb117c0e5b25
143 N215ac401ea9447a989ea11bb1630cd51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Colitis, Ulcerative
145 rdf:type schema:DefinedTerm
146 N2b0f1b608ac64db8aab10a9c969f45d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Secondary Prevention
148 rdf:type schema:DefinedTerm
149 N2ec90201e7f04acbb2d93b3580e95a3e rdf:first sg:person.0604330074.20
150 rdf:rest Nc008a7e981d7444aa6a66878c1905708
151 N342208bfdbd54923958081997aa50659 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Risk
153 rdf:type schema:DefinedTerm
154 N3494222cc8c7443bb6ae6d48f86d1dec schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N467a7fdd822442fa97b2a655e94d4c67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Humans
158 rdf:type schema:DefinedTerm
159 N47ddfe059cd0458b923fd610ed0df93a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Remission Induction
161 rdf:type schema:DefinedTerm
162 N553675eb66804d648ae6cd119c1f5d2d rdf:first sg:person.0606477677.70
163 rdf:rest N1f2d6d8c0c884a1dbf923d17c305155f
164 N593e64aedc264b5c9eaaee34bfd88564 schema:volumeNumber 106
165 rdf:type schema:PublicationVolume
166 N660022fc619141119b274f6b420ef24c schema:name doi
167 schema:value 10.1038/ajg.2011.72
168 rdf:type schema:PropertyValue
169 N6c54b0f4d0114cfd89cf546b4c50c75e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Rifamycins
171 rdf:type schema:DefinedTerm
172 N805590fd3e8f4f9baee9c5ddba0570a6 schema:name pubmed_id
173 schema:value 21407187
174 rdf:type schema:PropertyValue
175 N8532ca4e234b4c24bd00c09844625ac9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Anti-Bacterial Agents
177 rdf:type schema:DefinedTerm
178 N8bb4ce37169c43b1ac69eb117c0e5b25 rdf:first sg:person.01267435505.42
179 rdf:rest N2ec90201e7f04acbb2d93b3580e95a3e
180 N8d1701ccce9440c78cbf4ac17f17276a rdf:first sg:person.0722775106.31
181 rdf:rest Na71c81d3888c446ca52abc4379d23cae
182 N8d50da71932344d7a188a7764a0a3e23 schema:issueNumber 4
183 rdf:type schema:PublicationIssue
184 N8dd4598184854c1e86463cf548b7f294 schema:name dimensions_id
185 schema:value pub.1023776266
186 rdf:type schema:PropertyValue
187 Na5125856b5a3448abefad35e93f2f99c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Severity of Illness Index
189 rdf:type schema:DefinedTerm
190 Na71c81d3888c446ca52abc4379d23cae rdf:first sg:person.01031655740.00
191 rdf:rest N18605a0ed18144cc8df71b563e29fa60
192 Nb7e919dbb4be4cd7be07b13329ba23cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Crohn Disease
194 rdf:type schema:DefinedTerm
195 Nc008a7e981d7444aa6a66878c1905708 rdf:first sg:person.01336200702.64
196 rdf:rest rdf:nil
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1412991 schema:issn 0002-9270
204 1572-0241
205 schema:name The American Journal of Gastroenterology
206 schema:publisher Wolters Kluwer
207 rdf:type schema:Periodical
208 sg:person.01031655740.00 schema:affiliation grid-institutes:grid.59734.3c
209 schema:familyName Ullman
210 schema:givenName Thomas A
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031655740.00
212 rdf:type schema:Person
213 sg:person.01150145573.40 schema:affiliation grid-institutes:grid.411657.0
214 schema:familyName Abadir
215 schema:givenName A
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150145573.40
217 rdf:type schema:Person
218 sg:person.01251421433.66 schema:affiliation grid-institutes:grid.418161.b
219 schema:familyName Ford
220 schema:givenName Alexander C
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251421433.66
222 rdf:type schema:Person
223 sg:person.01267435505.42 schema:affiliation grid-institutes:grid.411657.0
224 schema:familyName Marshall
225 schema:givenName John K
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267435505.42
227 rdf:type schema:Person
228 sg:person.01336200702.64 schema:affiliation grid-institutes:grid.411657.0
229 schema:familyName Moayyedi
230 schema:givenName Paul
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336200702.64
232 rdf:type schema:Person
233 sg:person.0604330074.20 schema:affiliation grid-institutes:grid.266842.c
234 schema:familyName Talley
235 schema:givenName Nicholas J
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604330074.20
237 rdf:type schema:Person
238 sg:person.0606477677.70 schema:affiliation grid-institutes:grid.26790.3a
239 schema:familyName Abreu
240 schema:givenName Maria T
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606477677.70
242 rdf:type schema:Person
243 sg:person.0722775106.31 schema:affiliation grid-institutes:grid.411657.0
244 schema:familyName Khan
245 schema:givenName Khurram J
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722775106.31
247 rdf:type schema:Person
248 sg:pub.10.1007/bf01298873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027500057
249 https://doi.org/10.1007/bf01298873
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s10620-007-9760-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018618582
252 https://doi.org/10.1007/s10620-007-9760-1
253 rdf:type schema:CreativeWork
254 sg:pub.10.1023/a:1026648812439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038664726
255 https://doi.org/10.1023/a:1026648812439
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/ajg.2009.29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027606985
258 https://doi.org/10.1038/ajg.2009.29
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/ajg.2009.315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002445970
261 https://doi.org/10.1038/ajg.2009.315
262 rdf:type schema:CreativeWork
263 sg:pub.10.1038/ajg.2010.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002619249
264 https://doi.org/10.1038/ajg.2010.84
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/ajg.2011.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012980082
267 https://doi.org/10.1038/ajg.2011.58
268 rdf:type schema:CreativeWork
269 sg:pub.10.1038/nature08821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050498034
270 https://doi.org/10.1038/nature08821
271 rdf:type schema:CreativeWork
272 sg:pub.10.1111/j.1572-0241.2000.01842.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047651520
273 https://doi.org/10.1111/j.1572-0241.2000.01842.x
274 rdf:type schema:CreativeWork
275 sg:pub.10.1111/j.1572-0241.2007.01592.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053234582
276 https://doi.org/10.1111/j.1572-0241.2007.01592.x
277 rdf:type schema:CreativeWork
278 grid-institutes:grid.266842.c schema:alternateName Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia
279 schema:name Faculty of Health, University of Newcastle, Callaghan New South Wales, Australia
280 rdf:type schema:Organization
281 grid-institutes:grid.26790.3a schema:alternateName Miller School of Medicine, University of Miami, Miami, Florida, USA
282 schema:name Miller School of Medicine, University of Miami, Miami, Florida, USA
283 rdf:type schema:Organization
284 grid-institutes:grid.411657.0 schema:alternateName McMaster University Medical Centre, Hamilton, Ontario, Canada
285 schema:name McMaster University Medical Centre, Hamilton, Ontario, Canada
286 rdf:type schema:Organization
287 grid-institutes:grid.418161.b schema:alternateName Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
288 schema:name Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
289 rdf:type schema:Organization
290 grid-institutes:grid.59734.3c schema:alternateName The Mount Sinai School of Medicine, New York, New York, USA
291 schema:name The Mount Sinai School of Medicine, New York, New York, USA
292 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...